A new method to increase selectivity of transglutaminase mediated PEGylation of salmon calcitonin and human growth hormone.

Modification of therapeutic proteins and peptides by polyethylene glycol (PEG) conjugation is a well-known approach to improve the pharmacological properties of drugs. Several chemical procedures of PEG coupling are already in use but an alternative method based on microbial transglutaminase (mTGase) was recently devised. The enzyme catalyzes the link of mPEG-NH(2) to glutamines (Gln) of a substrate protein. In this case the advantage resides in the fact that usually only few Gln(s) in a protein are substrate of mTGase. In order to further restrict the selectivity of the enzyme, we investigated a new approach leading to the formation of a single conjugate isomer as well as for those proteins containing two or more Gln(s) as mTGase substrates. It was found that the addition of co-solvents in the reaction mixture influenced both the secondary structure of the targeted protein and the mTGase activity. The enzymatic PEGylation under these conditions yielded only mono- and selectively modified conjugates. The method was investigated with salmon calcitonin (sCT) and human growth hormone (hGH). In the case of sCT we also demonstrated the importance of site-selective conjugation for the preservation of in vivo activity.

[1]  Kang-Choon Lee,et al.  Isolation, Characterization, and Stability of Positional Isomers of Mono-PEGylated Salmon Calcitonins , 1999, Pharmaceutical Research.

[2]  P. Amodeo,et al.  Conformational flexibility in calcitonin: The dynamic properties of human and salmon calcitonin in solution , 1999, Journal of biomolecular NMR.

[3]  A. Motta,et al.  Sequential 1H NMR assignment and secondary structure determination of salmon calcitonin in solution. , 1989, Biochemistry.

[4]  A. Szabó,et al.  Effects of polyethylene glycol on stability of α-chymotrypsin in aqueous ethanol solvent , 2004 .

[5]  J. M. Harris,et al.  Effect of pegylation on pharmaceuticals , 2003, Nature Reviews Drug Discovery.

[6]  D. Wyss,et al.  Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. , 2002, Advanced drug delivery reviews.

[7]  Chih-Chuan Chang,et al.  A Novel High-Throughput Screening Method for Microbial Transglutaminases with High Specificity toward Gln141 of Human Growth Hormone , 2010, Journal of biomolecular screening.

[8]  D. Brems,et al.  Characterization and Stability of N-terminally PEGylated rhG-CSF , 1996, Pharmaceutical Research.

[9]  H. Michel,et al.  Positional isomers of monopegylated interferon alpha-2a: isolation, characterization, and biological activity. , 1997, Analytical biochemistry.

[10]  P. F. Nielsen,et al.  Transglutaminase‐mediated methods for site‐selective modification of human growth hormone , 2010, Biopolymers.

[11]  David J Brayden,et al.  Conjugation of salmon calcitonin to a combed-shaped end functionalized poly(poly(ethylene glycol) methyl ether methacrylate) yields a bioactive stable conjugate. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[12]  M. Bentley,et al.  Chemistry for peptide and protein PEGylation. , 2002, Advanced drug delivery reviews.

[13]  D. Gorenstein,et al.  Two-dimensional NMR and structure determination of salmon calcitonin in methanol. , 1991, Biochemistry.

[14]  E. Wainfan,et al.  The enzymatic formation of hydroxamic acids from glutamine and asparagine. , 1950, The Journal of biological chemistry.

[15]  V. Mukku,et al.  Long-acting Growth Hormones Produced by Conjugation with Polyethylene Glycol* , 1996, The Journal of Biological Chemistry.

[16]  S. Oh,et al.  Improved intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation: stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[17]  M. Paulsson,et al.  Transglutaminases: Protein Cross-Linking Enzymes in Tissues and Body Fluids , 1994, Thrombosis and Haemostasis.

[18]  F. Veronese,et al.  The Impact of PEGylation on Biological Therapies , 2012, BioDrugs.

[19]  B. Ranjbar,et al.  Effects of water-miscible solvents and polyhydroxy compounds on the structure and enzymatic activity of thermolysin. , 2006, Journal of biotechnology.

[20]  M. Hershfield,et al.  Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase. , 1988, The Journal of pediatrics.

[21]  Zhi-xin Xu,et al.  Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. , 2001, Bioconjugate chemistry.

[22]  F. Veronese,et al.  A new PEG-beta-alanine active derivative for releasable protein conjugation. , 2008, Bioconjugate chemistry.

[23]  S. Chae,et al.  Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[24]  H. Sato,et al.  Enzymatic procedure for site-specific pegylation of proteins. , 2002, Advanced drug delivery reviews.

[25]  S. Brocchini,et al.  Identification and insertion of 3-carbon bridges in protein disulfide bonds: a computational approach , 2007, Nature Protocols.

[26]  S. Brocchini,et al.  Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge. , 2007, Bioconjugate chemistry.

[27]  L. Denson Growth hormone therapy in children and adolescents: pharmacokinetic/pharmacodynamic considerations and emerging indications , 2008, Expert opinion on drug metabolism & toxicology.

[28]  J. V. Alstine,et al.  PEG-proteins: Reaction engineering and separation issues , 2006 .

[29]  D. Wyss,et al.  Identification of the major positional isomer of pegylated interferon alpha-2b. , 2000, Biochemistry.

[30]  M. Graham Pegaspargase: a review of clinical studies. , 2003, Advanced drug delivery reviews.

[31]  M. Sukumar,et al.  Non-native Intermediate Conformational States of Human Growth Hormone in the Presence of Organic Solvents , 2005, Pharmaceutical Research.

[32]  G. Pasut,et al.  Polymer-drug conjugation, recent achievements and general strategies , 2007 .

[33]  R. Epand,et al.  Determinants for calcitonin analog interaction with the calcitonin receptor N-terminus and transmembrane-loop regions. , 1996, Endocrinology.

[34]  Y. Youn,et al.  High-yield production of biologically active mono-PEGylated salmon calcitonin by site-specific PEGylation. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[35]  A. Drake,et al.  Comparative study of human and salmon calcitonin secondary structure in solutions with low dielectric constants. , 1993, The Journal of biological chemistry.

[36]  F. Veronese,et al.  Transglutaminase-mediated PEGylation of proteins: direct identification of the sites of protein modification by mass spectrometry using a novel monodisperse PEG. , 2009, Bioconjugate chemistry.

[37]  Jian Chen,et al.  Stability and conformational changes of transglutaminase from Streptomyces hygroscopicus in ethanol-aqueous medium , 2008 .

[38]  K. Yokoyama,et al.  Properties and applications of microbial transglutaminase , 2004, Applied Microbiology and Biotechnology.

[39]  Francesco M Veronese,et al.  PEGylation, successful approach to drug delivery. , 2005, Drug discovery today.

[40]  F. Veronese,et al.  Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase. , 2008, Advanced drug delivery reviews.

[41]  P. Sexton,et al.  Molecular pharmacology of the calcitonin receptor. , 2002, Receptors & channels.